A Study of TQ-B3525 on Tolerance and Pharmacokinetics

CTTQ

Status and phase: Enrolling; Phase 1

Conditions: Relapsed or Refractory Lymphoma or Advanced Cancer

Treatments: Drug: TQ-B3525

Study type: Interventional

Funder types: Industry

Identifiers

NCT03510767

TQ-B3525-I-01

Details and patient eligibility

About

To study the pharmacokinetic characteristics of TQ-B3525 in the human body, recommend a reasonable regimen for subsequent research.

Enrollment: 60 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Relapsed or refractory lymphoma or advanced solid tumor that diagnosed Pathologically or cytologically diagnosed
• ECOG PS≤1
• Adequate blood cell counts, kidney function and liver function
• Patients should participate in the study voluntarily and sign informed consent

Exclusion criteria

• Patients with immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency disease, or organ transplant history
• Hypertension (systolic BP ≥150 mmHg, diastolic BP ≥90 mmHg) still uncontrollable by one medication
• Hepatitis B virus patients with active replication (DNA> 500 cps / mL), hepatitis C

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

60 participants in 1 patient group

TQ-B3525

Experimental group

Treatment:

Drug: TQ-B3525